Education
About Us
Working with TipRanks
Follow Us
Cormedix Inc. (CRMD)
:CRMD
CRMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.60 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)4.04M
Market Cap
$862.55M
Enterprise Value$695.76M
Total Cash (Recent Filing)$190.71M
Total Debt (Recent Filing)$435.25K
Price to Earnings (P/E)14.8
Beta1.64
Next Earnings
Nov 06, 2025EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding78,058,710
10 Day Avg. Volume2,869,793
30 Day Avg. Volume4,038,376
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)5.63
Price to Sales (P/S)10.97
P/FCF Ratio-9.40
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue5.73
Enterprise Value/Gross Profit5.99
Enterprise Value/Ebitda13.30
Forecast
1Y Price Target
$20.60Price Target Upside86.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe acquisition of Melinta Therapeutics is viewed positively due to significant synergies and the potential to unlock greater hospital and acute care revenue.
Product DevelopmentRezzayo's potential expanded indication in adult allogenic blood and marrow transplant patients could drive meaningful upside for CorMedix.
Revenue GrowthCorMedix delivered 2Q25 financial results with total revenues of $39.7M for DefenCath, which was above expectations and is likely appreciated by investors.
Bears Say
Company ValuationChallenges and headwinds are seen, most notably public company valuations for acute care companies.
Market SentimentInvestor caution around the anti-infective space likely resulted in a stock reaction of a decrease in value compared to the market.
Cormedix News
CRMD FAQ
What was Cormedix Inc.’s price range in the past 12 months?
Cormedix Inc. lowest stock price was $5.60 and its highest was $17.43 in the past 12 months.
What is Cormedix Inc.’s market cap?
Cormedix Inc.’s market cap is $862.55M.
When is Cormedix Inc.’s upcoming earnings report date?
Cormedix Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 34 days.
How were Cormedix Inc.’s earnings last quarter?
Cormedix Inc. released its earnings results on Aug 07, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.187 by $0.103.
Is Cormedix Inc. overvalued?
According to Wall Street analysts Cormedix Inc.’s price is currently Undervalued.
Does Cormedix Inc. pay dividends?
Cormedix Inc. does not currently pay dividends.
What is Cormedix Inc.’s EPS estimate?
Cormedix Inc.’s EPS estimate is 0.43.
How many shares outstanding does Cormedix Inc. have?
Cormedix Inc. has 78,058,710 shares outstanding.
What happened to Cormedix Inc.’s price movement after its last earnings report?
Cormedix Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.187. Following the earnings report the stock price went down -9.54%.
Which hedge fund is a major shareholder of Cormedix Inc.?
Currently, no hedge funds are holding shares in CRMD
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.60 (86.43% Upside)
$20.60 (86.43% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 24.4%
Last 30 Days ▲ 24.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.41%
12-Months-Change
Fundamentals
Return on Equity
38.35%
Trailing 12-Months
Asset Growth
337.55%
Trailing 12-Months
Company Description
Cormedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant strategic progress through the acquisition of Melinta, strong financial results, and clinical advancements. However, increased operating expenses and limited visibility on the LDO rollout present challenges.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$20.60
▲(86.43% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.24% Insiders
9.16% Mutual Funds
10.18% Other Institutional Investors
67.60% Public Companies and Individual Investors